ARMC5 and congenital adrenal hyperplasia: Additionally, primary bilateral macronodular adrenal hyperplasia and ARMC5 mutation both associated with somatic mutation, along with therapeutic agents like metyrapone, osilodrostat, and 11 beta-hydroxylase inhibitors, are likely to remain highly relevant research targets.